Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chlamydia felis (formerly Chlamydophila felis) is a Gram-negative, obligate intracellular bacterial pathogen that primarily infects cats, causing conjunctivitis, rhinitis, and respiratory disease. It is transmitted via close contact, especially through ocular secretions. The bacterium has two distinct morphological forms: the infectious elementary body (EB) and the replicative reticulate body (RB). Diagnosis is best achieved by PCR on conjunctival or oropharyngeal swabs. Treatment typically involves systemic antibiotics, with doxycycline as the first-line choice for at least four weeks. The organism does not survive well outside the host and is sensitive to common disinfectants. It is considered a therapeutic target for antimicrobial therapy in feline medicine. While historically classified in the genus Chlamydophila, modern taxonomy places it in the genus Chlamydia[1][5][7].
Inhibition of bacterial protein synthesis (doxycycline, tetracyclines), Inhibition of DNA gyrase (fluoroquinolones)[2][5]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chlamydia felis (formerly Chlamydophila felis) (C. felis).